CytoSorbents Q4 2023 GAAP EPS $(0.12) Beats $(0.14) Estimate, Sales $8.700M Miss $9.285M Estimate
Portfolio Pulse from Benzinga Newsdesk
CytoSorbents (NASDAQ:CTSO) reported Q4 2023 GAAP EPS of $(0.12), beating the $(0.14) estimate, but missed sales estimates with $8.700M compared to the expected $9.285M. This represents a 7.36% decrease in sales compared to the same period last year.
March 14, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CytoSorbents reported a mixed Q4 2023 with an EPS beat but a miss on sales estimates, showing a decrease in sales compared to last year.
The mixed results with an EPS beat but a sales miss could lead to a neutral short-term impact on CTSO's stock price. Investors might react positively to the EPS beat, indicating better-than-expected profitability. However, the miss on sales estimates and the year-over-year decrease in sales could raise concerns about the company's growth trajectory, potentially offsetting the positive impact of the EPS beat.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100